Introduction
sphamide, were considered for a treatment trial with extracorporeal immunoadsorption onto staphylococcal protein A Major organ system involvement in systemic lupus ( Table 1) . While all patients had proteinuria, two patients erythematosus (SLE ) may occur in the heart, lungs, (nos 1 and 8) suffered also from renal failure. Low platelet counts were found in patients nos 6 and 8. Lupus activity was assessed using the SLE activity measure (SLAM ) [9] . of the local ethics board. SLAM, systemic lupus erythematosus activity measure [9] ; LN, lupus nephritis; n/a, not available; ANA. antinuclear antibodies; homo, homogeneous; speck, speckled; Ab, antibodies; max, maximum during active disease; cor; cardiac involvement; pulmo, pulmonary complication; arth, arthritis; CNS, cerebral manifestation; vas, vasculitis and thrombosis; liv, liver involvement; Pred, prednisolone; Aza, azathioprine; CyP, cyclophosphamide; Px, plasmapheresis with cyclophosphamide; Clq, hydroxychloroquine; Ig, immunoglobulins.
Immunoadsorption and immunosuppression
Immunoadsorption was carried out as previously described [10] . In brief, blood was drawn from the patient by using a double-lumen jugular or subclavian catheter and plasma was processed over either of two SPA sepharose columns (Immunosorba, Excorim, Lund, Sweden) using a plasma flow monitor (Citem 10, Excorim, Lund, Sweden). Immunoadsorption was started with one relative body plasma volume (BPV ) and adjusted according to the elimination rate of IgG, aiming at complete removal after the end of the procedure. Six patients were treated every other day, but patients nos 6 and 8 were treated every day. No immunosuppression or cytotoxic drugs were administered at the beginning of the immunoadsorption for 3 weeks (induction period ). The patients were put on oral cyclophosphamide for 3-6 months when remission had been obtained. Patients nos 4 and 6 received i.v. cyclophosphamide on the recommendation of their physicians.
Laboratory investigations
Venous blood samples were drawn before, during, and after the immunoadsorption for blood counts, biochemistry, coagulation parameters, complement fractions C3 and C4, immunoglobulins IgG, IgM, and IgA. IgG subclasses were detected by a sandwich enzyme-linked immunosorbent assay (ELISA) ( The Binding Site, Heidelberg, Germany) and results of random samples were confirmed by radial immunodiffusion (The Binding Site). C1q-and C3-fixing circulating immune complexes were determined by ELISA (IBL, Hamburg, Germany). Antinuclear antibodies were detected by standard immunofluorescence test. Crithidia lucilia antigen titres (Dr W. F. Gross, Bad Bramstedt, Germany) were tested before and after completion of immunoadsorption therapy. Anti-ds-DNA antibodies were tested by ELISA (Elias, Freiburg, Germany). Anti-ds-DNA IgG3 antibodies were detected by a double sandwich ELISA using ds-DNA coated immunoplates (Elias) and a polyclonal sheep antihuman IgG3 serum (kindly provided by Dr Bradford, Birmingham, UK ) and a peroxidase-conjugated anti-sheep antibody (Dianova, Hamburg, Germany). Figure 1a ). Overall daily prednisolone requirement was reduced from mean serum creatinine declined from 2.3±2.1 mg/dl to 0.9±0.2 mg/dl ( Table 1) . Proteinuria declined in all 41 mg/day±51 to 18 mg/day±15, P=0.26. The mean cumulative monthly prednisolone intake before patients during immunoadsorption and no relapse was observed after the treatment ( Figure 1c ). Patient #1 immunoadsorption was 1219±1502 mg compared with 549±452 mg 1 month after immunoadsorption presented with scintillating scotoma and blurred vision.
Funduscopy
Complement levels were reduced in most patients at the beginning of immunoadsorption and increased to immunoadsorption [10] .
normal or almost normal levels during the period of immunoadsorption. Patient no. 3 had a congenital
Immunological results
complement C4 deficiency and only C3 returned to normal values. When C1q-and C3-fixing circulating immune complexes were initially detected, they were All patients were Crithidia antigen positive at the eliminated during a single immunoadsorption procedbeginning and became negative during or shortly after ure (published previously [11] ). ending immunoadsorption. Anti-ds-DNA antibody levels declined although the initial levels varied over a wide range (Table 1 ). The decline of anti-ds-DNA
Adverse effects
antibodies and anti-ds-DNA-IgG3 antibodies is shown in Figure 2a ,b. Six patients exhibited anti-phospholipid Immunoadsorption itself was well tolerated by all antibodies (anti-thromboplastin and anticardiolipin) patients during most of the treatments. Therapy was and patients nos 2, 6 and 8 had anti-phospholipid stopped in only one patient because of deteriorating associated clinical complications ( Table 1) . In all cases renal function. In this patient the coincidence of severe antibody titres were lowered below detection limit respiratory and metabolic alkalosis with supple-(data not shown) but reappeared during cyclophosmentation of i.v. calcium and phosphate buffer (used phamide treatment. An increase in platelet counts was for regeneration of the SPA columns) led to an increase of the activity product for calcium hydrogen phosphate (-logAP 5.8, relative supersaturation 0.9) and octacalcium phosphate (-logAP 43.7, relative supersaturation 1.3) in the urine [12] with subsequent spontaneous tubular crystal formation [13] .
Long-term outcome
All patients were discharged from the hospital and followed-up on half-yearly intervals. At last follow-up, SLAM index further declined to 4.5±3.6 and none of the patients required cyclophosphamide after conversion to azathioprine or prednisolone monotherapy. Three patients (nos 7, 2, 3) were again admitted to hospital for active lupus disease and treated with pulse prednisolone. No patient went into end-stage renal disease.
Discussion
Progress in the therapy of SLE has increased survival during the last 20 years [14] . Satisfactory remission in many patients with moderate and severe SLE can be achieved with i.v. cyclophosphamide and/or methylprednisolone. Attempts to improve survival and morbidity in these patients by the combination of cyclophosphamide with plasmapheresis were shown to be ineffective in controlled clinical trials [5, 7, 15] . The elimination of pathogenic autoantibodies by removal of plasma and substitution of albumin or fresh frozen plasma is neither efficient nor does it suppress the from plasmapheresis in SLE: (i) Plasma exchange leads immunoadsorption was performed, the relapse in patient no. 4 who to an average decrease for immunoglobulin concentrawas treated with i.v. cyclophosphamide after immunoadsorption is tion to only 60% per session, and (ii) plasmapheresis indicated (i.v. CyP). Only one patient (no. 8) showed an increase in is usually carried out on alternate days and limited to IgG3 anti-ds-DNA antibody levels. This patient received i.v. immunoglobulins prior to immunoadsorption (see Table 1 ).
one BPV, mainly because of the risk of bleeding due [16 ] tried to remove
The effect of immunoadsorption is mainly dependent on the quantity of treated plasma, the frequency of anti-DNA antibodies from a patient by plasma perfusion over a charcoal device. Others have used immunoadsorptions, and the antibody kinetics, which can be influenced by the co-administration of immunoimmunoadsorption onto dextran sulphate [17, 18] , phenylalanine [19] [20] [21] , tryptophan [22] , or SPA [23, 24] globulins. Intravenous immunoglobulin application is a treatment modality for SLE [35] and combination in patients with SLE and other autoimmune diseases. Clinical improvement could be demonstrated in some of immunoadsorption and subsequent i.v. immunoglobulin therapy was thought to potentiate each others of these cases but no reports were suitable to clearly identify the benefit of immunoadsorption, since con-effect on autoantibody and immune complex formation while avoiding infectious complications. But whenever ventional immunosuppression was also given to the patient. When we used immunoadsorption in a treat-i.v. immunoglobulins were administered to a patient undergoing immunoadsorption, elimination rate of ment-resistant case of SLE where even synchronization therapy did not induce a remission, recovery was anti-ds-DNA antibodies and complement levels decreased. In patient no. 8 who received iv immunobrought by immunoadsorption onto SPA irrespective of immunosuppressants [25] . Our experience with globulins and immunoadsorption on a regular basis, platelet counts first increased when immunoglobulin immunoadsorption monotherapy in eight cases with SLE showed that all except one patient achieved a treatment was discontinued, indicating that high concentrations of administered immunoglobulins compete complete or partial remission with well-preserved organ function. All patients had been pre-treated with various with low levels of pathogenic autoantibodies for SPA binding sites. We concluded that i.v. immunoglobulins immunosuppressants and cytotoxic drugs. At the time of the manuscript revision, relapse-free remission has should be avoided when immunoadsorption is selected as treatment for SLE and other autoimmune diseases continued in four patients.
Following complete elimination of immunoglobulins [36 ] .
In conclusion, immunoadsorption onto SPA is highly by immunoadsorption a rapid redistribution is noted, because around 50% of IgG is distributed in the effective regarding the elimination of autoantibodies and circulating immune complexes and might induce extravascular space. Repeated treatments were necessary to suppress disease activity. We noted that altern-a remission in patients with severe SLE. It is an acceptable alternative treatment option in patients with ate-day immunoadsorption was not enough to achieve low autoantibody levels, and we started to treat the SLE when other therapies are ineffective or contraindicated. Whether immunoadsorption onto SPA is more patients on a daily basis. Running such a protocol with treated plasma volumes of more than 30 l within effective than classical cyclophosphamide treatment must be proven by a controlled clinical trial. a week would certainly cause problems if classical plasma exchange were used. It was also shown that
